Fidelity Investments
COCP icon

Fidelity Investments’s Cocrystal Pharma COCP Stock Holding History

Fidelity Investments’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-334
Closed -$411 – 5597
2026
Q1 		$337 Buy
+334
New +$345 ﹤0.01% 5194
2024
Q1 		– Sell
-4
Closed -$7 – 5408
2023
Q4 		$7 Sell
4
-183
-98% -$325 ﹤0.01% 5350
2023
Q3 		$350 Buy
187
+96
+105% +$241 ﹤0.01% 4746
2023
Q2 		$217 Buy
91
+87
+2,175% +$211 ﹤0.01% 4894
2023
Q1 		$8 Buy
+4
New +$9 ﹤0.01% 5193

Other funds holding COCP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fidelity Investments's COCP Position: Q2 2026 in Review

Fidelity Investments sold out of Cocrystal Pharma (COCP) in Q2 2026, closing a stake of 334 shares — an estimated $411 sold.

Fidelity Investments first reported a position in COCP in Q1 2023 and held it in 5 quarters. The position peaked at $350 in Q3 2023. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • Fidelity Investments reported no remaining Cocrystal Pharma position as of Q2 2026 after selling out during the quarter.
  • Fidelity Investments sold 334 Cocrystal Pharma shares in Q2 2026, an estimated $411.
  • Fidelity Investments first reported a position in Cocrystal Pharma in Q1 2023 and held it in 5 quarters.
  • Fidelity Investments's Cocrystal Pharma position peaked at $350 in Q3 2023.
  • 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.